Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.

EBioMedicine | 2019

Despite the success of antiretroviral therapy (ART), latent HIV-1 continues to persist in a long-lived population of resting memory CD4+ T cells within those who are infected. Finding a safe and effective means to induce latency reversal (LR) during ART to specifically expose this latent HIV-1 cellular reservoir for immune elimination has been a major barrier to a functional cure.

Pubmed ID: 30952614 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NIH AIDS Reagent Program (tool)

RRID:SCR_023191

NIH HIV Reagent Program has been managed under contract by American Type Culture Collection (ATCC) since 2020. ATCC shall maintain the NIH HIV Reagent Program through identification, acquisition, production, receipt, storage, maintenance, distribution and disposal of biological and chemical research organisms and materials for HIV and other infectious diseases for use in basic and translational research.

View all literature mentions

U-118MG (tool)

RRID:CVCL_0633

Cell line U-118MG is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

CD107a (antibody)

RRID:AB_396134

This monoclonal targets CD107a (LAMP-1)

View all literature mentions

CD14-PE, human (antibody)

RRID:AB_2660171

This monoclonal targets CD14

View all literature mentions

TZM-bl (cell line)

RRID:CVCL_B478

Cell line TZM-bl is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions